JP2005528359A - うつ病の治療のためのブプレノルフィンの投与方法 - Google Patents

うつ病の治療のためのブプレノルフィンの投与方法 Download PDF

Info

Publication number
JP2005528359A
JP2005528359A JP2003577780A JP2003577780A JP2005528359A JP 2005528359 A JP2005528359 A JP 2005528359A JP 2003577780 A JP2003577780 A JP 2003577780A JP 2003577780 A JP2003577780 A JP 2003577780A JP 2005528359 A JP2005528359 A JP 2005528359A
Authority
JP
Japan
Prior art keywords
buprenorphine
dosage
depression
transdermal
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003577780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528359A5 (enExample
Inventor
カイコ，ロバート，エフ．
サンチェス，ラミロ
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2005528359A publication Critical patent/JP2005528359A/ja
Publication of JP2005528359A5 publication Critical patent/JP2005528359A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2003577780A 2002-03-20 2003-03-20 うつ病の治療のためのブプレノルフィンの投与方法 Pending JP2005528359A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
PCT/US2003/008796 WO2003079945A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (2)

Publication Number Publication Date
JP2005528359A true JP2005528359A (ja) 2005-09-22
JP2005528359A5 JP2005528359A5 (enExample) 2006-05-11

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003577780A Pending JP2005528359A (ja) 2002-03-20 2003-03-20 うつ病の治療のためのブプレノルフィンの投与方法

Country Status (12)

Country Link
US (1) US20030181475A1 (enExample)
EP (1) EP1485051B1 (enExample)
JP (1) JP2005528359A (enExample)
AT (1) ATE394097T1 (enExample)
AU (1) AU2003224742A1 (enExample)
CY (1) CY1108217T1 (enExample)
DE (1) DE60320770D1 (enExample)
DK (1) DK1485051T3 (enExample)
ES (1) ES2305457T3 (enExample)
PT (1) PT1485051E (enExample)
SI (1) SI1485051T1 (enExample)
WO (1) WO2003079945A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504183A (ja) * 2003-09-02 2007-03-01 ノボシス アーゲー オピオイド鎮痛剤およびアロエ組成物を含む経皮製剤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
MXPA05006334A (es) * 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
UA81056C2 (en) 2003-07-25 2007-11-26 Euro Celtic S A Method for treatment of dependence withdrawal in pregnant women by transdermal administration of buprenorphine
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
SMT201900357T1 (it) 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
AU2012351806C1 (en) 2011-12-15 2016-06-16 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2790703B1 (en) * 2011-12-15 2019-06-12 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DK0484543T3 (da) * 1990-04-24 1996-01-22 Teijin Ltd Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US6165499A (en) * 1996-03-25 2000-12-26 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504183A (ja) * 2003-09-02 2007-03-01 ノボシス アーゲー オピオイド鎮痛剤およびアロエ組成物を含む経皮製剤
JP2012188447A (ja) * 2003-09-02 2012-10-04 Acino Ag オピオイド鎮痛剤およびアロエ組成物を含む経皮製剤

Also Published As

Publication number Publication date
DE60320770D1 (de) 2008-06-19
EP1485051A1 (en) 2004-12-15
PT1485051E (pt) 2008-07-09
EP1485051B1 (en) 2008-05-07
ATE394097T1 (de) 2008-05-15
AU2003224742A1 (en) 2003-10-08
US20030181475A1 (en) 2003-09-25
SI1485051T1 (sl) 2008-10-31
CY1108217T1 (el) 2014-02-12
DK1485051T3 (da) 2008-09-08
EP1485051A4 (en) 2006-05-24
ES2305457T3 (es) 2008-11-01
WO2003079945A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
JP2005528359A (ja) うつ病の治療のためのブプレノルフィンの投与方法
JP5856573B2 (ja) 経皮デリバリーシステム
JP2011252020A (ja) 依存性退薬症状の治療
JP2010500992A (ja) アルツハイマー病の経皮的治療法及び経皮的治療システム
CN106456561A (zh) 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
CN105764495A (zh) 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
CA3135552C (en) Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
ES2299871T3 (es) Tratamiento pre-operatorio del dolor post-operatorio.
US7413748B2 (en) Transdermal buprenorphine to treat pain in sickle cell crisis
EP3725306A1 (en) Transdermal therapeutic system
EP1795189A2 (en) Method of administering buprenorphine to treat depression
US20200330404A1 (en) Transdermal therapeutic system
WO2013026547A1 (en) Rotigotine in the treatment of hemispatial neglect and other deficits following stroke
AU2012201164A1 (en) Transdermal delivery systems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100223